Maike Hansen
Maike Hansen

Research group of Maike Hansen joins Oncode Institute

The Oncode Institute has invited Maike Hansen and her research group to join the institute as of 1 January 2024. The Oncode institute is an independent research institute that unites leading oncology scientists. Hansen's group has been selected based on the quality of their science, expertise, and potential to contribute to the Oncode Institute's mission of accelerating breakthroughs in cancer research and translating discoveries from the lab to new treatments for patients more rapidly.

Regulation of gene expression in tumour cells

Maike Hansen is researching the regulation of gene expression in various model systems. Biological systems, including cancer cells, exhibit a phenomenon known as gene expression noise. Gene expression noise can lead to significant variations between cells, even if the cells are genetically identical. This may contribute to resistance to treatments such as chemotherapy because some cells within the tumour may possess characteristics that make them less responsive to specific medications.
Maike Hansen's group is investigating how variability in gene expression is controlled in tumour cells and what role these differences between cells play in the development of resistance to chemotherapy.

“Alongside the Oncode community, we will expand our research to study the role of gene expression noise and how it is critical in cancer progression. In particular, Oncode is composed of oncologists and immunologists that I am excited to collaborate with, and provides access to a network of facilities and equipment that is invaluable. In addition, the base funding will allow us to expand our group and buy some critical equipment,´ explains Maike Hansen. 

Oncode Institute

In addition to Hansen's group, the Oncode Institute has selected nine other
 research groups. With this expansion, the Oncode Institute now comprises 62 research groups, distributed across 13 universities and research institutes throughout the Netherlands. The new researchers bring their expertise in fundamental oncological research, with a clear connection to translational and clinical research. They also contribute knowledge in the field of emerging technologies, including AI, protein design, and biophysics.